Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
AGM presentation is now available on the website:
www.reneuron.com/investors/presentations
^make that "inappropriate"
grizzlyb
Yes, I noticed that too, which is interesting.
However don't take my word for it [RP centre stage and CTX relegated], take the CEO's word for it. Look back at this interview from 21st March:
www.youtube.com/watch?v=DhIz6Jmz8ZU
He basically doesn't even bother talking about the CTX line. Around 1 minute he says, if it's no good they'll "toss it". All in all I thought very dismissive at the time and completely unappropriate given trial patients undergoing invasive surgery with hope.
I've been (and remain) a holder for well over a decade, toptiger! I'm still nursing considerable losses.
I don't mean to be dramatic, that's honestly the way I feel about it. It seems to me the company has shifted its focus from CTX to RP because of the markedly better efficacy being shown, and therefore at least the short term SP is completely dependent on the update on that trial.
Feels like we're basically all-in on Retinal now. If efficacy has continued, we'll all be quids in. Many quids in. If not SP is going to nosedive.
It's not a bad bet. At this price, you've got a binary option on 3 or 4 times your investment or 75% loss. Far better than heads or tails!
Plus the price should creep up in the run up to mid-October now.
It's about time Fosun stumped up some milestone payments too
This *must* be the conference at which RENE will be giving the update on the retinal pigmentosa trial:
www.aao.org/annual-meeting
At least we now have a definite timeline.
SP, I assume, will hover around 200p in the meantime unless we hear any other news. Strange how the spike back to 250p was short-lived over the last couple of weeks. Makes you wonder what that was all about!
ReNeuron presenting at this ophthalmic conference tomorrow. Possible update on retinal trial???
www.ophthalmology-futures.com/retina-forum-2019/
I reckon we'll start to see momentum building now in the run up to October
I reckon we'll start to see momentum building now in the run up to October
Yeah, that's unlikely to be the reason Nickprice100 seeing as RENE ditched their critical limb ischemia therapy about 10 years ago.
Looking good folks!
I don't want to sound negative but I've been here so many times before with RENE. People awaiting news pushes up the SP, the news comes but doesn't say what we want it to (i.e. RP trial update this time) and then they release a string of lame RNS's to try and stop the SP dropping off in the run up to the next big event. But it doesn't work, and down it goes.
It is probably worth selling now (especially with Woodford still around) and buying back in September BUT as I've said before I'm pretty sure if I try that there'll be a power RNS out of the blue and I'll be reaching for the razor blades.
Best not to look until September, I suppose. If that's actually possible :)
Because we've had 2 RNS's telling us so
Feels like they're trying to drip-feed RNS's to stop the SP nose-diving in the run up to October. Hopefully it will work and Woodford sells have dried up.
Certainly shows they're seriousss
Completely misleading though egg. They can move to another broker but they can't get their money out.
Eh?
I listened to it, Phil and it all sounded very positive although I have to admit they did say they wouldn't realistically be looking for further partnering for RP until the October results are available because it's only when they've got that data that they can realise the true value. But who knows, plenty of other things could happen in the meantime.
There are two strategies for investors here:
1) try to trade in and out on dips and peaks short term
2) play the long game for potentially huge gains
We didn't get an update on the RP trial but the rest of the results are very encouraging with multiple mentions of increased interest from 3rd parties, low cash burn with injections of cash from Fosun and exciting new opportunities including this:
"We are now working to develop further new allogeneic cell lines, including NK and T-cells (the cells that can be modified to attack cancer cells), as potential therapeutic agents for out-licensing to third parties."
RENE haven't really gone for the big C before. That line buried in the RNS could on its own have huge implications.
Investment strategy 1) is perfectly reasonable and is responsible for the deramping comments you see on here today. What type 2) investors like more than anything else is a curve-ball RNS out of nowhere that announces a deal and shoots the SP through the roof leaving type 1)'ers with their pants down :)
All looking good for type 2)'ers. Just hold your RENE and hold your nerve because this is increasingly looking like a definite multi-bagger for those with the patience to see it out.
GLA